{
  "symbol": "NKTX",
  "company_name": "Nkarta Inc",
  "ir_website": "https://ir.nkartatx.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Nkarta to Participate in an Upcoming Investor Conference",
          "url": "https://ir.nkartatx.com/news-releases/news-release-details/nkarta-participate-upcoming-investor-conference-5",
          "content": "[Skip to content](#lfg-main-content)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo-new.svg)](https://www.nkartatx.com/) [](# \"menu\")[](# \"mobile menu\")\n\n#  Investors \n\n##  Press Release Details \n\n# \n\nNkarta to Participate in an Upcoming Investor Conference\n\nNov 26, 2024 at 7:02 AM EST\n\n[Download PDF](/node/9456/pdf)\n\nSOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:\n\n**7****th****Annual Evercore HealthCONx Conference** December 4, 20242:10 p.m. ET ‚Äì fireside chat\n\nA simultaneous webcast of the event will be available on the Investors section of Nkarta‚Äôs website, [www.nkartatx.com](https://www.globenewswire.com/Tracker?data=dd-sS-XE9QFMLgBKVFHjg5cuQTD8gZtH5i6sFWYuFw-kQjuS4DKk3azsplXPhwGMBi_s5LzpPkztmUAwOyHpug==), and a replay will be archived on the website for approximately 90 days.\n\n**About Nkarta** Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company‚Äôs website at [www.nkartatx.com](https://www.globenewswire.com/Tracker?data=dd-sS-XE9QFMLgBKVFHjg58KvlPgj8tgHZnUt7shdbfFBbJHS8rEHhoS2EGG9jNEqfGlVwewsUb2AmxbWZwnEA==).\n\n**Nkarta Media/Investor Contact:** Greg MannNkarta, Inc.gmann@nkartatx.com\n\n![](https://ml.globenewswire.com/media/ZmU2NzkxZGMtYmViMS00YjBkLWI5NjktNTRhZDBkMjhkYTM4LTExMDk5NjA=/tiny/Nkarta-Inc-.png)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo_white.svg)](https://www.nkartatx.com/)\n\nNkarta, Inc. 1150 Veterans Blvd South San Francisco CA 94080\n\ninfo@nkartatx.com\n\n[linkedin](https://www.linkedin.com/company/nkarta-therapeutics-inc/)\n\n¬© 2024 Nkarta, Inc..  All rights reserved\n"
        },
        {
          "title": "Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights",
          "url": "https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-third-quarter-2024-financial-results-and",
          "content": "[Skip to content](#lfg-main-content)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo-new.svg)](https://www.nkartatx.com/) [](# \"menu\")[](# \"mobile menu\")\n\n#  Investors \n\n##  Press Release Details \n\n# \n\nNkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights\n\nNov 07, 2024 at 4:02 PM EST\n\n[Download PDF](/node/9401/pdf)\n\n  * _First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies_\n  *  _Enrollment in Ntrust-2 expected to initiate by year-end 2024_\n  *  _Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025_\n  *  _No further NKX019 development in lymphoma planned_\n  *  _Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases_\n  *  _Cash balance of $405.3 million on September 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027_\n\n\n\nSOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2024.\n\n\"We‚Äôre encouraged by the early progress that we‚Äôve made in the clinical investigation of NKX019 for autoimmune disease,‚Äù said Paul J. Hastings, CEO of Nkarta. ‚ÄúHaving dosed a first patient in both Ntrust-1 and the Columbia University Irving Medical Center IST, our learnings can help us optimize the execution of our current and future clinical trials. This includes our Ntrust-2 trial, which is on track to initiate enrollment later this year. Safety and accessibility are paramount in autoimmune disease, and we believe that an off-the-shelf, engineered NK cell therapy has the greatest potential to help patients.‚Äù\n\nHastings continued, ‚ÄúWe have decided to forgo future development of NKX019 in non-Hodgkin lymphoma. In reviewing the clinical data from the latest cohort of patients with large B-cell lymphoma and the evolving treatment landscape, Nkarta will focus its efforts on autoimmune diseases, where we believe NKX019 has potential to transform patient care.‚Äù\n\n**Clinical development of NKX019 for autoimmune diseases advances**\n\n  * Dosing of the first patient in Ntrust-1, a clinical trial of NKX019 for the treatment of lupus nephritis. As previously announced, the first Ntrust-1 patient entered screening in June 2024.\n  * Dosing of the first patient in the IST of NKX019 in systemic lupus erythematosus at Columbia University Irving Medical Center (CUIMC). As previously announced, the CUIMC IST was initiated in July 2024.\n  * Both studies continue to enroll participants.\n\n\n\n**Anticipated autoimmune milestones 2024-2025**\n\n  * Initiation of patient enrollment expected by year-end 2024 in Ntrust-2, a clinical trial of NKX019 for the treatment of systemic sclerosis, myositis and vasculitis. As previously announced, the Investigational New Drug (IND) Application for Ntrust-2 cleared in June 2024.\n  * Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025.\n\n\n\n**Update for NKX019 in non-Hodgkin lymphoma (NHL)**\n\n  * A cohort of seven patients with heavily pretreated large B-cell lymphoma (LBCL) whose disease progressed following treatment with a CD19 CAR T-cell therapy received NKX019 on Days 0, 3, and 7 following lymphodepletion.\n  * There were no cases of Grade >2 cytokine release syndrome (CRS) and no cases of immune effector cell-associated neurotoxicity (ICANS).\n  * Five patients achieved a partial response after a first cycle of treatment. One of these five patients achieved a complete response with >6 months durability after receiving a second cycle of treatment.\n  * Nkarta aims to report final data from the LBCL cohort at a future medical conference.\n  * Nkarta will forgo further development in NHL and prioritize development efforts on autoimmune diseases.\n\n\n\n**Third Quarter 2024 and Recent Financial Highlights**\n\n  * Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of $405.3 million as of September 30, 2024.\n  * Research and development (R&D) expenses were $25.3 million for the third quarter of 2024. Non-cash stock-based compensation expense included in R&D expense was $1.8 million for the third quarter of 2024.\n  * General and administrative (G&A) expenses were $8.5 million for the third quarter of 2024. Non-cash stock-based compensation expense included in G&A expense was $2.3 million for the third quarter of 2024.\n  * Net loss was $28.3 million, or $0.39 per basic and diluted share, for the third quarter of 2024. This net loss includes non-cash charges of $5.8 million that consisted primarily of share-based compensation and depreciation expenses.\n\n\n\n**Financial Guidance**\n\n  * Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into late 2027.\n\n\n\n**About NKX019** NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies.\n\n**About Ntrust‚Ñ¢ Clinical Trials in Autoimmune Disease** Ntrust-1 and Ntrust-2 are multi-center, open label, dose escalation clinical trials that build on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy. Both trials will assess the safety of NKX019 in people living with autoimmune diseases as well as its ability to enable long-term remissions via a ‚Äúreset‚Äù of the immune system through the elimination of pathogenic B cells. Per the trial protocols, patients receive three-dose cycles of NKX019 at 1 billion or 1.5 billion cells per dose following single-agent lymphodepletion with cyclophosphamide, an agent with an established safety profile across autoimmune diseases. Leveraging the engineering of NKX019, no patients in either trial will receive supplemental cytokines or antibody-based therapeutics. This approach is designed to evaluate the single-agent activity of NKX019 and facilitate a more rapid path to regulatory approval.\n\nIn the Ntrust-1 study ([NCT06557265](https://www.globenewswire.com/Tracker?data=3s-yTwWANZyyTvlSReHc4bP9foDkGEF0H8nQjAZ4mysLNZ9lxPX3G1lZdWiRfGa9ggWReM2EOIdMuErE_RdTSUAXych1HEvR9tN9QPnQrFs=)), patients with refractory lupus nephritis receive three-dose cycles of NKX019 following lymphodepletion. Patients in Ntrust-1 may also receive additional cycles to restore response.\n\nOnce initiated, Ntrust-2 will enroll patients with systemic sclerosis (scleroderma), idiopathic inflammatory myopathy (myositis), and ANCA-associated vasculitis into parallel cohorts, and NKX019 will be dosed on Days 0, 3, and 7, a regimen that may be advantageous across all Nkarta clinical trials. Each trial is designed to initially enroll up to 12 patients.\n\n**About the Investigator-Sponsored Clinical Trial of NKX019 for Systemic Lupus Nephritis** The single-center, single-arm, open-label Phase 1 investigator-sponsored clinical trial is designed to enroll up to 6 patients with systemic lupus erythematosus, regardless of renal involvement, and will evaluate safety and clinical outcomes in a potentially different population than Ntrust-1. Translational and biomarker studies, including autoantibodies, cytokine profiles and pharmacokinetics are also planned. Patients receive NKX019 following single-agent lymphodepletion with cyclophosphamide. The clinical trial is being led by Anca D. Askanase, M.D., M.P.H., Director, Lupus Center at Columbia University Irving Medical Center and the Director of Rheumatology Clinical Trials.\n\n**About Nkarta** Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company‚Äôs website at [www.nkartatx.com](https://www.globenewswire.com/Tracker?data=YkqCVijxd_5NRpaZkG530lYhJKHP5poh4AqtHeGaL7Ke6IA_UUWd2BKb3P3HGV5DrBC6tqIirxCXN0npgLyfew==).\n\n**Cautionary Note on Forward-Looking Statements** Statements contained in this press release regarding matters that are not historical facts are ‚Äúforward-looking statements‚Äù within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as \"anticipates,\" \"believes,\" \"expects,\" \"intends,\" ‚Äúplans,‚Äù ‚Äúpotential,‚Äù \"projects,‚Äù ‚Äúwould‚Äù and \"future\" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta‚Äôs expectations regarding any or all of the following: Nkarta‚Äôs position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019 (including initiation of further clinical trials such as Ntrust-2 and the future availability and disclosure of clinical data and other updates from Nkarta‚Äôs clinical trials); the therapeutic potential, accessibility, tolerability, advantages, and safety profile of NK cell therapies, including NKX019 for the treatment of autoimmune diseases, lupus, systemic sclerosis, myositis, and vasculitis, and NHL; and Nkarta‚Äôs expected cash runway. Interim clinical data for NKX019 included in this press release are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data on existing patients become available.\n\nBecause such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta‚Äôs limited operating history and historical losses; Nkarta‚Äôs lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta‚Äôs ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta‚Äôs dependence on the clinical success of NKX019; that Nkarta may be delayed in initiating, enrolling or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta‚Äôs ability to obtain, maintain and protect its intellectual property; Nkarta‚Äôs dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; and the complexity of the manufacturing process for CAR NK cell therapies.\n\nThese and other risks and uncertainties are described more fully in Nkarta‚Äôs filings with the Securities and Exchange Commission (‚ÄúSEC‚Äù), including the ‚ÄúRisk Factors‚Äù section of Nkarta‚Äôs Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 13, 2024, and Nkarta‚Äôs other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\n\n**Nkarta, Inc.****Condensed Statements of Operations****(in thousands, except share and per share data)****(Unaudited)**  \n---  \n**Three Months Ended September 30,**| **Nine Months Ended September 30,**  \n**2024**| **2023**| **2024**| **2023**  \nOperating expenses  \nResearch and development| $| 25,250| $| 22,194| $| 73,617| $| 73,451  \nGeneral and administrative| 8,544| 7,100| 23,654| 27,014  \nTotal operating expenses| 33,794| 29,294| 97,271| 100,465  \nLoss from operations| (33,794| )| (29,294| )| (97,271| )| (100,465| )  \nOther income, net:  \nInterest income| 5,453| 3,616| 14,423| 10,651  \nOther (expense) income, net| (3| )| 33| (7| )| 67  \nTotal other income, net| 5,450| 3,649| 14,416| 10,718  \nNet loss| $| (28,344| )| $| (25,645| )| $| (82,855| )| $| (89,747| )  \nNet loss per share, basic and diluted| $| (0.39| )| $| (0.52| )| $| (1.26| )| $| (1.83| )  \nWeighted average shares used to compute net loss per share, basic and diluted| 73,563,316| 49,062,799| 65,941,355| 48,985,373  \n  \n**Nkarta, Inc.****Condensed Balance Sheets****(in thousands)****(Unaudited)**  \n---  \n**September 30,****2024**| **December 31,****2023**  \n**Assets**  \nCash, cash equivalents, restricted cash and investments| $| 405,265| $| 250,932  \nProperty and equipment, net| 76,231| 79,326  \nOperating lease right-of-use assets| 38,804| 39,949  \nOther assets| 11,734| 8,678  \nTotal assets| $| 532,034| $| 378,885  \n**Liabilities and stockholders' equity**  \nAccounts payable, accrued and other liabilities| $| 15,712| $| 17,261  \nOperating lease liabilities| 85,449| 88,339  \nTotal liabilities| 101,161| 105,600  \nStockholders‚Äô equity| 430,873| 273,285  \nTotal liabilities and stockholders‚Äô equity| $| 532,034| $| 378,885  \n  \n**Nkarta Media/Investor Contact:** Greg MannNkarta, Inc.gmann@nkartatx.com\n\n![](https://ml.globenewswire.com/media/ZmVmZDg4YjMtM2YxYy00OTk2LTliOWYtNmI3YmQyNzNjMmUzLTExMDk5NjA=/tiny/Nkarta-Inc-.png)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo_white.svg)](https://www.nkartatx.com/)\n\nNkarta, Inc. 1150 Veterans Blvd South San Francisco CA 94080\n\ninfo@nkartatx.com\n\n[linkedin](https://www.linkedin.com/company/nkarta-therapeutics-inc/)\n\n¬© 2024 Nkarta, Inc..  All rights reserved\n"
        },
        {
          "title": "PDF Version of Nkarta to Participate in an Upcoming Investor Conference",
          "url": "https://ir.nkartatx.com/node/9456/pdf",
          "content": "\n"
        },
        {
          "title": "PDF Version of Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights",
          "url": "https://ir.nkartatx.com/node/9401/pdf",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "7th Annual Evercore HealthCONx Conference",
          "url": "https://ir.nkartatx.com/events/event-details/7th-annual-evercore-healthconx-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo-new.svg)](https://www.nkartatx.com/) [](# \"menu\")[](# \"mobile menu\")\n\n#  Investors \n\n##  Events Details \n\n## 7th Annual Evercore HealthCONx Conference \n\n###  Dec 4, 2024 at 2:10 PM EST \n\n[Add to Outlook](/node/9461/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Nkarta, Inc. - 7th Annual Evercore HealthCONx Conference &dates=20241204T191000Z/20241204T191000Z&details=Event Details: https://ir.nkartatx.com/events/event-details/7th-annual-evercore-healthconx-conference%0A%0AWebcast: https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=nktx&url=https://wsw.com/webcast/evercore44/nktx/2406159&location=&trp=false&sprop=&sprop=name:)\n\n[View Webcast](https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=nktx&url=https%3A//wsw.com/webcast/evercore44/nktx/2406159)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo_white.svg)](https://www.nkartatx.com/)\n\nNkarta, Inc. 1150 Veterans Blvd South San Francisco CA 94080\n\ninfo@nkartatx.com\n\n[linkedin](https://www.linkedin.com/company/nkarta-therapeutics-inc/)\n\n¬© 2024 Nkarta, Inc..  All rights reserved\n"
        },
        {
          "title": "View Webcast for 7th Annual Evercore HealthCONx Conference",
          "url": "https://wsw.com/webcast/evercore44/register.aspx?conf=evercore44&page=nktx&url=https%3A//wsw.com/webcast/evercore44/nktx/2406159",
          "content": "![Header Logo](images/logo.png)\n\n![](images/mobile-logo.png)\n\n# Register for the 7th Annual Evercore HealthCONx Conference\n\nNkarta, Inc. \n\nPresenting at: 12/4/2024 2:10 PM (ET)\n\nFirst Name First name required.\n\nLast Name Last name required.\n\nCompany Company name required.\n\nE-mail E-mail required. Email is not valid\n\nYou must have cookies enabled in order to register for this event.\n\n![Summitcast](/images/summitcast_logo_sm_black.png)\n\n[![Summitcast](/images/resources/images/summitcast_logo_md_white.png)](https://twstevents.com/divisions/summitcast/)¬© 2024 twstevents.com - Unauthorized recording or downloading of this event is not permitted. \n"
        },
        {
          "title": "Stifel 2024 Healthcare Conference",
          "url": "https://ir.nkartatx.com/events/event-details/stifel-2024-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo-new.svg)](https://www.nkartatx.com/) [](# \"menu\")[](# \"mobile menu\")\n\n#  Investors \n\n##  Events Details \n\n## Stifel 2024 Healthcare Conference\n\n###  Nov 19, 2024 at 10:55 AM EST \n\n[View Webcast](https://wsw.com/webcast/stifel96/register.aspx?conf=stifel96&page=nktx&url=https%3A//wsw.com/webcast/stifel96/nktx/2136174)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo_white.svg)](https://www.nkartatx.com/)\n\nNkarta, Inc. 1150 Veterans Blvd South San Francisco CA 94080\n\ninfo@nkartatx.com\n\n[linkedin](https://www.linkedin.com/company/nkarta-therapeutics-inc/)\n\n¬© 2024 Nkarta, Inc..  All rights reserved\n"
        },
        {
          "title": "View Webcast for Stifel 2024 Healthcare Conference",
          "url": "https://wsw.com/webcast/stifel96/register.aspx?conf=stifel96&page=nktx&url=https%3A//wsw.com/webcast/stifel96/nktx/2136174",
          "content": "![Header Logo](images/logo.png)\n\n![](images/mobile-logo.png)\n\n# Register for Stifel 2024 Healthcare Conference\n\nNkarta, Inc. \n\nPresenting at: 11/19/2024 10:55 AM (ET)\n\nFirst Name First name required.\n\nLast Name Last name required.\n\nCompany Company name required.\n\nE-mail E-mail required. Email is not valid\n\nYou must have cookies enabled in order to register for this event.\n\n![Summitcast](/images/summitcast_logo_sm_black.png)\n\n[![Summitcast](/images/resources/images/summitcast_logo_md_white.png)](https://twstevents.com/divisions/summitcast/)¬© 2024 \n\ntwstevents.com - Unauthorized recording or downloading of this event is not permitted.\n\ntwstevents.com\n"
        },
        {
          "title": "H.C. Wainwright 26th Annual Global Investment Conference",
          "url": "https://ir.nkartatx.com/events/event-details/hc-wainwright-26th-annual-global-investment-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo-new.svg)](https://www.nkartatx.com/) [](# \"menu\")[](# \"mobile menu\")\n\n#  Investors \n\n##  Events Details \n\n## H.C. Wainwright 26th Annual Global Investment Conference \n\n###  Sep 10, 2024 at 12:30 PM EDT \n\n[View Webcast](https://journey.ct.events/view/d02f00e0-6b5f-4680-a350-a97583d6ffdf)\n\n[![logo](/sites/g/files/knoqqb54386/themes/site/nir_pid3714/dist/images/logo_white.svg)](https://www.nkartatx.com/)\n\nNkarta, Inc. 1150 Veterans Blvd South San Francisco CA 94080\n\ninfo@nkartatx.com\n\n[linkedin](https://www.linkedin.com/company/nkarta-therapeutics-inc/)\n\n¬© 2024 Nkarta, Inc..  All rights reserved\n"
        },
        {
          "title": "View Webcast for H.C. Wainwright 26th Annual Global Investment Conference",
          "url": "https://journey.ct.events/view/d02f00e0-6b5f-4680-a350-a97583d6ffdf",
          "content": "An error has occurred. This application may no longer respond until reloaded. [Reload]() üóô\n"
        }
      ]
    }
  ]
}